Transcode Therapeutics, Inc. (RNAZ): R&D Expense
$13.42M
Year ended 2025-12-31
$17.44M
Trailing 12 months to 2026-06-30
+9.5%
3-year compound annual growth
+116.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $13.42M | +38.3% | 2026-04-15, From 2025-01-01 |
| 2024-12-31 | $9.71M | -20.9% | 2026-04-15, From 2024-01-01 |
| 2023-12-31 | $12.26M | +19.9% | 2025-04-15, From 2023-01-01 |
| 2022-12-31 | $10.23M | +271.6% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $2.75M | +868.1% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $284.5K | n/a | 2022-03-31, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $13.42M | +38.3% |
| Cypherpunk Technologies Inc. (CYPH) | 2025-12-31 | $25.67M | -55.1% |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $1.63M | n/a |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $52.65M | +56.7% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $17.19M | -15.2% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $13.70M | +13.9% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $46.71M | +225.8% |
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | $44.84M | -18.9% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $70.09M | +117.5% |
Compare RNAZ, CYPH, APUS, ACRS side by side · Screen every company in Pharmaceutical Preparations ↗